SG11202103659VA - Compositions and methods for the treatment of smooth muscle dysfunction - Google Patents
Compositions and methods for the treatment of smooth muscle dysfunctionInfo
- Publication number
- SG11202103659VA SG11202103659VA SG11202103659VA SG11202103659VA SG11202103659VA SG 11202103659V A SG11202103659V A SG 11202103659VA SG 11202103659V A SG11202103659V A SG 11202103659VA SG 11202103659V A SG11202103659V A SG 11202103659VA SG 11202103659V A SG11202103659V A SG 11202103659VA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- treatment
- methods
- smooth muscle
- muscle dysfunction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767457P | 2018-11-14 | 2018-11-14 | |
| US201962873064P | 2019-07-11 | 2019-07-11 | |
| PCT/IB2019/059805 WO2020100089A2 (en) | 2018-11-14 | 2019-11-14 | Compositions and methods for the treatment of smooth muscle dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103659VA true SG11202103659VA (en) | 2021-06-29 |
Family
ID=68655594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103659VA SG11202103659VA (en) | 2018-11-14 | 2019-11-14 | Compositions and methods for the treatment of smooth muscle dysfunction |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220133849A1 (he) |
| EP (1) | EP3880229A2 (he) |
| JP (1) | JP2022511596A (he) |
| KR (1) | KR20210094567A (he) |
| CN (1) | CN113164555A (he) |
| AU (1) | AU2019381329A1 (he) |
| CA (1) | CA3114691A1 (he) |
| IL (1) | IL282739A (he) |
| MX (1) | MX2021003778A (he) |
| SG (1) | SG11202103659VA (he) |
| TW (1) | TW202039531A (he) |
| WO (1) | WO2020100089A2 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023218278A1 (en) | 2022-05-12 | 2023-11-16 | Urovant Sciences Gmbh | Long-term gene therapy for overactive bladder |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0557459B1 (en) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunctional selectable fusion genes |
| EP0804590A1 (en) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| US7169764B1 (en) | 1995-10-05 | 2007-01-30 | Arch Development Corporation | Promoter for smooth muscle cell expression |
| US6239117B1 (en) | 1997-02-13 | 2001-05-29 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for regulating bladder smooth muscle tone |
| US7030096B1 (en) | 1997-02-13 | 2006-04-18 | Albert Einstein College Of Medicine Of Yeshiva University | Method of enhancing relaxation of penile smooth muscle by introduction of DNA encoding maxi-K potassium channel protein |
| US6271211B1 (en) | 1997-02-13 | 2001-08-07 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for regulating penile smooth muscle tone |
| US6150338A (en) | 1997-02-13 | 2000-11-21 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for alleviating erectile dysfunction |
| CN1621094A (zh) | 2003-11-26 | 2005-06-01 | 犹太大学阿尔伯特爱因斯坦医学院 | 用于调节平滑肌张力的基因转移 |
| US8361490B2 (en) | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
| US20080269159A1 (en) | 2007-04-27 | 2008-10-30 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for regulation of smooth muscle cells and blood pressure |
| US20090042208A1 (en) * | 2007-07-31 | 2009-02-12 | Davies Kelvin P | Assays for erectile and bladder dysfunction and vascular health |
| EP2525777B1 (en) | 2010-01-20 | 2019-05-29 | UroGen Pharma Ltd. | Material and method for treating internal cavities |
| US20140142191A1 (en) | 2011-07-20 | 2014-05-22 | Theracoat Ltd. | Production of thermoreversible hydrogels for therapeutic applications |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US20160184455A1 (en) | 2013-08-05 | 2016-06-30 | Ion Channel Innovations, Llc | Compositions and methods for treating smooth muscle dysfunction |
| US20170136106A1 (en) | 2015-11-17 | 2017-05-18 | Allergan, Inc. | Botulinum toxin administration for treatment of neurogenic detrusor overactivity associated urinary incontinence |
| EP3419652A1 (en) | 2016-02-22 | 2019-01-02 | Allergan, Inc. | Improved bladder injection paradigm for administration of botulinum toxins |
| US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| JP2020520383A (ja) | 2017-05-12 | 2020-07-09 | イオン チャネル イノベーションズ, エルエルシーIon Channel Innovations, Llc | 突発性の過活動膀胱症候群及び排尿筋過活動を処置するための組成物及び方法 |
-
2019
- 2019-11-14 US US17/294,296 patent/US20220133849A1/en active Pending
- 2019-11-14 EP EP19809173.8A patent/EP3880229A2/en active Pending
- 2019-11-14 WO PCT/IB2019/059805 patent/WO2020100089A2/en unknown
- 2019-11-14 CN CN201980082403.6A patent/CN113164555A/zh active Pending
- 2019-11-14 TW TW108141448A patent/TW202039531A/zh unknown
- 2019-11-14 KR KR1020217018054A patent/KR20210094567A/ko active Search and Examination
- 2019-11-14 AU AU2019381329A patent/AU2019381329A1/en active Pending
- 2019-11-14 CA CA3114691A patent/CA3114691A1/en active Pending
- 2019-11-14 MX MX2021003778A patent/MX2021003778A/es unknown
- 2019-11-14 JP JP2021517820A patent/JP2022511596A/ja active Pending
- 2019-11-14 SG SG11202103659VA patent/SG11202103659VA/en unknown
-
2021
- 2021-04-28 IL IL282739A patent/IL282739A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113164555A (zh) | 2021-07-23 |
| MX2021003778A (es) | 2021-07-21 |
| KR20210094567A (ko) | 2021-07-29 |
| WO2020100089A2 (en) | 2020-05-22 |
| CA3114691A1 (en) | 2020-05-22 |
| JP2022511596A (ja) | 2022-02-01 |
| TW202039531A (zh) | 2020-11-01 |
| EP3880229A2 (en) | 2021-09-22 |
| IL282739A (he) | 2021-06-30 |
| WO2020100089A3 (en) | 2020-07-23 |
| US20220133849A1 (en) | 2022-05-05 |
| AU2019381329A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268406A (he) | תכשירים ושיטות לטיפול מחלות של המוגלובין | |
| IL275626A (he) | תכשירים ושיטות לטיפול שטח | |
| GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
| IL290150A (he) | תרכובות ושיטות לטיפול בכאב כרוני | |
| IL287796A (he) | תכשירים ושיטות לטיפול במחלות מתווכות באמצעות atpase | |
| IL275182A (he) | תכשירים ושיטות לטיפול במצבים מטבוליים | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| IL272937A (he) | תכשירים ושיטות לטיפול במחלות המערבות פיברוזיס | |
| IL276135A (he) | תכשירים ושיטות לשימוש | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| IL280348A (he) | תכשירים ושיטות לטיפול בפני השטח | |
| IL280414A (he) | תכשירי ביסמוט-תיול ושיטות שימוש | |
| IL272121A (he) | תכשיר ושיטות לטיפול בקוצר ראייה | |
| IL279634A (he) | תכשירים ושיטות לטיפול ומניעה של הפרעות עיצביות | |
| IL290348A (he) | הרכבים ושיטות לטיפול בפני השטח | |
| SG11202104053TA (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| IL277805A (he) | שימוש בגבוקסאדול בטיפול בהפרעות שימוש בחומר | |
| IL282739A (he) | תרכובות ושיטות לטיפול בחוסר תיפקוד בשרירים החלקים | |
| GB201810923D0 (en) | Compositions and method of treatment | |
| IL280262A (he) | הרכבים ושיטות לטיפול בסרטן | |
| IL280868A (he) | תכשירים ושיטות לטיפול בפגיעה ריאתית אקוטית | |
| IL276228A (he) | תרכובות ותכשירים לטיפול בכאב | |
| IL291184A (he) | תכשירים ושיטות לטיפול בהפרעות הקשורות עם תפקוד לקוי או אובדן של clec16a | |
| EP3801581A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE CONTRACTURES |